Science & Research
Aditxt Subsidiary's Protein Analysis Platform Shows Promise in Breast Cancer Treatment Study
A study published in npj Precision Oncology found that Ignite Proteomics' protein analysis platform provided more predictive insight into metastatic breast cancer treatment outcomes than traditional methods, potentially improving treatment selection.
Oncotelic Therapeutics Featured in Editorial Highlighting Biotech's Shift Toward Science-Driven Asset Valuation
A BioMedWire editorial highlights how biotechnology companies like Oncotelic Therapeutics are increasingly seeing scientific progress translate into measurable financial value through fair-value accounting frameworks, with Oncotelic's 45% stake in GMP Bio valued at over $1 billion.
Oragenics Reports Early Progress in Phase IIa Trial of Intranasal Concussion Therapy
Oragenics Inc. has enrolled two patients and administered eight doses in its Phase IIa trial for ONP-002, a potential first-in-class intranasal treatment for mild traumatic brain injury, addressing a significant unmet medical need in a market with no FDA-approved pharmacological therapies.
Soligenix Gains European Orphan Drug Designation for Behçet's Disease Therapy SGX945
The European Commission granted orphan drug designation to Soligenix's SGX945 for treating Behçet's disease, validating the therapy's potential and providing regulatory and commercial incentives for development in a rare disease area with significant unmet need.
LIXTE Biotechnology's LB-100 Represents Novel Cancer Treatment Approach Through PP2A Inhibition
LIXTE Biotechnology Holdings is advancing LB-100, a first-in-class PP2A inhibitor designed to enhance existing cancer therapies by making tumors more responsive to chemotherapy and immunotherapy in multiple clinical programs targeting solid tumors with significant unmet medical need.
Golden Cariboo Discovers Deep Mineralization at Quesnelle Gold Quartz Mine Property
Golden Cariboo Resources Ltd. has identified potential new mineralization approximately 600 meters below surface at its British Columbia property, advancing the company's understanding of the site's long-term potential as it progresses toward a mineral resource estimate.
New Oral Rinse Demonstrates Superior Gingivitis Protection in Saliva Environment
ioRinse Ultra has shown complete elimination of gingivitis-causing bacteria within 30 seconds in saliva-inclusive testing, addressing a critical gap in traditional oral rinse evaluation that could transform daily oral care routines.
MAX Power Mining Expands Lawson Natural Hydrogen Discovery with 3D Seismic Results
MAX Power Mining Corp. has reported preliminary 3D seismic survey results that significantly expand its Lawson Natural Hydrogen system in Saskatchewan, delineating a large structural closure and identifying high-priority drill targets that enhance the project's commercial potential.
Molecular Testing Gains Importance in Complex CNS Cancer Diagnosis and Treatment
Molecular analysis is becoming crucial for identifying and treating complex central nervous system tumors, which traditional methods often miss, with companies like CNS Pharmaceuticals advancing targeted drug development.
NanoViricides Highlights NV-387 as Potential Measles Treatment Amid Global Outbreak Concerns
NanoViricides announced its antiviral drug candidate NV-387 may address the growing global measles outbreak, potentially complementing vaccination efforts by reducing transmission and treating infected patients.
Soligenix CEO Advocates for Patient-Centric Drug Reformulation to Improve Treatment Access and Adherence
Soligenix CEO Christopher Schaber argues that reformulating therapies to better align with patients' daily lives can enhance treatment access, adherence, and clinical trial success, reflecting a broader industry shift toward patient-centered drug development.
Cybin Reports Strong Q2 2025 Results and Advances Late-Stage Neuropsychiatry Programs
Cybin Inc. has reported strong institutional demand in its second-quarter 2025 results while advancing multiple late-stage clinical programs for mental health treatments, positioning the company for key 2026 data readouts that could significantly impact neuropsychiatry treatment options.
Annovis Bio Advances Alzheimer's Treatment with Phase 3 Trial Progress and Promising Biomarker Data
Annovis Bio reports significant progress in its Phase 3 Alzheimer's trial with full site activation and promising biomarker data showing buntanetap's disease-modifying potential, positioning the company for potential regulatory submission.
UK Government Invests $18.4 Million in Quantum Computing Projects Targeting 2036 Breakthrough
The UK government has allocated $18.4 million to support quantum computing initiatives that aim to surpass current supercomputers by 2036, representing a strategic investment in transformative technology with potential applications across multiple industries.
Cybin to Present Neuropsychiatry Pipeline at Jefferies Global Healthcare Conference
Cybin Inc. will present its late-stage neuropsychiatry pipeline including breakthrough-designated depression treatment at the Jefferies Global Healthcare Conference, highlighting the company's progress in developing novel mental health therapies.
Quantum Critical Metals Achieves 93% Gallium Recovery from Mica, Paving Way for North American Supply
Quantum Critical Metals Corp. has achieved a 93% gallium recovery rate from mica samples, potentially establishing a new domestic source for the critical metal amid China's export controls and strengthening Western supply chain security.
GeoVax Advances Vaccine Programs Amid Global Health Crises Despite Financial Losses
GeoVax Labs reported significant progress in its mpox, COVID-19, and cancer vaccine programs during Q3 2025, positioning the company as a key player in addressing urgent public health needs while navigating financial challenges.
Former NASA Engineer Releases Book on Anxiety Relief Through Energy Therapy
Mark L. Fox, former Space Shuttle Chief Engineer, has published a book promoting PEMF therapy as a drug-free solution for anxiety, chronic pain, and sleep disorders based on two decades of research.
Astatine-211 Breakthrough Offers Targeted Cancer Treatment Alternative
Texas A&M University researchers have developed a cancer treatment using astatine-211 that targets malignant cells while sparing healthy tissue, representing a significant advancement in precision radiotherapy.
March Biosciences Receives FDA RMAT Designation for CAR-T Therapy Targeting Aggressive T-Cell Lymphoma
The FDA granted RMAT designation to March Biosciences' MB-105 CAR-T therapy for relapsed T-cell lymphoma, potentially accelerating treatment development for patients with limited survival options.
NanoViricides Secures $6 Million in Funding to Advance Antiviral Drug Development
NanoViricides has raised $6 million through a registered direct offering and concurrent private placement, providing crucial capital to advance its broad-spectrum antiviral drug candidates including NV-387 for respiratory infections and NV-HHV-1 for shingles treatment.
Oncotelic and Sapu Bioscience Define Sub-15 nm Nanoparticles as New Frontier in Drug Delivery
Oncotelic Therapeutics and Sapu Bioscience have published a landmark review establishing sub-15 nm nanoparticles as a breakthrough drug delivery platform capable of overcoming limitations of current therapies through enhanced tissue penetration and reduced toxicity.
Engineer-Author Takahiro Yonemura Releases 70th Title with Recycled Brain Part Two Global Launch
Takahiro Yonemura's latest science fiction manga release marks his 70th published work while exploring the intersection of technology and human emotion through cross-cultural storytelling.
Byrne Elliott Music Releases Cinematic Instrumental Exploring Second Coming of Christ
Byrne Elliott Music has released "La Seconda Venuta di Cristo," an instrumental composition that musically interprets the second coming of Jesus Christ and its apocalyptic implications, now available on major streaming platforms.
HOPE Therapeutics Launches Revolutionary One-Day Depression Treatment Protocol in Florida
NRx Pharmaceuticals' subsidiary HOPE Therapeutics has initiated Florida's first deployment of a rapid one-day TMS protocol for treatment-resistant depression, potentially transforming care for millions suffering from depression and PTSD.
MAX Power Mining Advances Canada's First Natural Hydrogen Well with Saskatchewan Drill Permit
MAX Power Mining has secured regulatory approval to drill Canada's first dedicated natural hydrogen well, marking a significant step in exploring naturally occurring hydrogen as a potential clean energy source.
NanoViricides Receives Regulatory Approval for Phase II MPox Trial in Democratic Republic of Congo
NanoViricides has received regulatory approval to begin Phase II clinical trials for its broad-spectrum antiviral drug NV-387 to treat MPox in the Democratic Republic of Congo, representing a potential breakthrough in antiviral therapy.
MAX Power Mining Advances Canada's First Natural Hydrogen Drill Program Through Academic Collaboration
MAX Power Mining is strengthening partnerships with the Petroleum Technology Research Center and University of Regina to advance Canada's inaugural natural hydrogen exploration program along Saskatchewan's Genesis Trend, marking a significant step in North America's clean energy transition.
Polypill Strategy Shows Promise for Heart Failure Treatment, Improving Outcomes and Medication Adherence
A new study demonstrates that a once-daily combination pill for heart failure patients significantly improves heart function, reduces hospitalizations, and enhances quality of life compared to traditional multi-pill regimens.
PCSK9 Inhibitor Combined with Statin Shows Significant LDL Reduction in Heart Transplant Patients
A clinical trial demonstrates that adding the PCSK9 inhibitor alirocumab to statin therapy reduces LDL cholesterol by more than 50% in heart transplant patients, though it did not prevent the development of cardiac allograft vasculopathy.